Abstract
Glucocorticoids have been used in modern clinical practice for over fifty years. Although they have demonstrated potent anti-inflammatory and immunosuppressive activities, their association with debilitating and lifethreatening side effects has been a major drawback. Recent insights into glucocorticoid biology have lent support to the hypothesis that the glucocorticoid anti-inflammatory activities could be dissociated from their adverse side effects. Inspired by these biological findings, the search for dissociated glucocorticoid receptor agonists has intensified. Antagonists of the glucocorticoid receptor that offer therapeutic benefits for the treatment of diseases such as diabetes have also been pursued. These efforts have been partly focused on the development of tissue, especially liver, selective glucocorticoid receptor antagonists, which are thought to have improved safety profiles. This review offers a summary of the research and development activities in this field and covers journal and patent publications from 2003 to March 2006.
Keywords: Glucocorticoid, glucocorticoid receptor, transactivation, transrepression, agonist, dissociation, antagonist, tissue selectivity
Current Topics in Medicinal Chemistry
Title: Recent Progress in the Discovery of Novel Glucocorticoid Receptor Modulators
Volume: 8 Issue: 6
Author(s): Hidenori Takahashi, Hossein Razavi and David Thomson
Affiliation:
Keywords: Glucocorticoid, glucocorticoid receptor, transactivation, transrepression, agonist, dissociation, antagonist, tissue selectivity
Abstract: Glucocorticoids have been used in modern clinical practice for over fifty years. Although they have demonstrated potent anti-inflammatory and immunosuppressive activities, their association with debilitating and lifethreatening side effects has been a major drawback. Recent insights into glucocorticoid biology have lent support to the hypothesis that the glucocorticoid anti-inflammatory activities could be dissociated from their adverse side effects. Inspired by these biological findings, the search for dissociated glucocorticoid receptor agonists has intensified. Antagonists of the glucocorticoid receptor that offer therapeutic benefits for the treatment of diseases such as diabetes have also been pursued. These efforts have been partly focused on the development of tissue, especially liver, selective glucocorticoid receptor antagonists, which are thought to have improved safety profiles. This review offers a summary of the research and development activities in this field and covers journal and patent publications from 2003 to March 2006.
Export Options
About this article
Cite this article as:
Takahashi Hidenori, Razavi Hossein and Thomson David, Recent Progress in the Discovery of Novel Glucocorticoid Receptor Modulators, Current Topics in Medicinal Chemistry 2008; 8 (6) . https://dx.doi.org/10.2174/156802608783955737
DOI https://dx.doi.org/10.2174/156802608783955737 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High Content Screening for G Protein-Coupled Receptors Using Cell-Based Protein Translocation Assays
Combinatorial Chemistry & High Throughput Screening Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Self-Assembled Micelles of Amphiphilic PEGylated Drugs for Cancer Treatment
Current Drug Targets Morusin Inhibits Human Osteosarcoma via the PI3K-AKT Signaling Pathway
Current Pharmaceutical Biotechnology Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Diagnostic, Prognostic and Therapeutic Potential of Heat Shock Proteins in Schistosomiasis and Bladder Cancer: A Review
Letters in Drug Design & Discovery Network Pharmacology-based Prediction and Verification of Shikonin for Treating Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Chemical Inhibition of Matrix Metalloproteinases for Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Advancements in the Treatment and Repair of Tendon Injuries
Current Tissue Engineering (Discontinued) Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets Current Phthalocyanines Delivery Systems in Photodynamic Therapy: An Updated Review
Current Medicinal Chemistry Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry